Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$34.63 +3.4%	$32.38	$27.34 ▼ $60.87	$6.36B	0.13	1.36 million shs	1.81 million shs
SRPT Sarepta Therapeutics	$17.11 -0.7%	$39.48	$16.97 ▼ $162.95	$1.68B	0.61	2.14 million shs	4.73 million shs
TEVA Teva Pharmaceutical Industries	$16.76 +1.2%	$16.72	$12.47 ▼ $22.80	$19.22B	0.6	10.29 million shs	8.94 million shs
UTHR United Therapeutics	$284.27 +0.1%	$301.12	$266.98 ▼ $417.82	$12.82B	0.57	446,107 shs	462,927 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	0.00%	+1.85%	+20.45%	+2.06%	-21.81%
SRPT Sarepta Therapeutics	0.00%	-14.79%	-54.64%	-73.19%	-89.17%
TEVA Teva Pharmaceutical Industries	0.00%	-1.25%	-0.09%	+8.90%	+3.11%
UTHR United Therapeutics	0.00%	-2.23%	-10.14%	-7.79%	-10.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LEGN Legend Biotech	2.3839 of 5 stars	3.5	1.0	0.0	3.4	1.7	0.6
SRPT Sarepta Therapeutics	4.6827 of 5 stars	4.2	2.0	4.2	2.2	1.7	1.9
TEVA Teva Pharmaceutical Industries	4.0143 of 5 stars	4.6	3.0	0.0	2.0	1.7	1.9
UTHR United Therapeutics	4.9926 of 5 stars	4.3	5.0	4.6	2.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	120.04% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$60.88	255.79% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.99% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$393.08	38.28% Upside

Current Analyst Ratings Breakdown

Latest LEGN, UTHR, SRPT, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$627.24M	10.15	N/A	N/A	$5.70 per share	6.08
SRPT Sarepta Therapeutics	$1.90B	0.88	$2.44 per share	7.02	$15.99 per share	1.07
TEVA Teva Pharmaceutical Industries	$16.54B	1.16	$3.36 per share	4.98	$4.74 per share	3.53
UTHR United Therapeutics	$2.88B	4.46	$28.40 per share	10.01	$144.34 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.56	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.37	0.86	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.34	10.34	6.22	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest LEGN, UTHR, SRPT, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	0.30	5.20	5.07
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
SRPT Sarepta Therapeutics	86.68%
TEVA Teva Pharmaceutical Industries	54.05%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
SRPT Sarepta Therapeutics	7.70%
TEVA Teva Pharmaceutical Industries	0.55%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

LEGN, UTHR, SRPT, and TEVA Headlines

Recent News About These Companies

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

June 29 at 4:19 AM | americanbankingnews.com

United Therapeutics Corporation (UTHR) - Yahoo Finance

June 28 at 2:23 PM | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

June 28 at 6:13 AM | insidertrades.com

United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study

June 28 at 5:24 AM | msn.com

UTHR United Therapeutics Corporation - Seeking Alpha

June 27 at 7:22 PM | seekingalpha.com

Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

June 27 at 5:55 PM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

June 27 at 8:19 AM | marketbeat.com

Robeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 27 at 5:02 AM | marketbeat.com

Contrasting United Therapeutics (NASDAQ:UTHR) and Journey Medical (NASDAQ:DERM)

June 27 at 2:26 AM | americanbankingnews.com

United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment

June 26, 2025 | tipranks.com

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

June 26, 2025 | zacks.com

3D Systems and TISSIUM Achieve FDA Approval for Innovative 3D-Printed Solution in Peripheral Nerve Repair

June 26, 2025 | quiverquant.comQ

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 26, 2025 | insidertrades.com

Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Price Target at $393.08

June 26, 2025 | americanbankingnews.com

Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Corp

June 25, 2025 | gurufocus.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 25, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells 3,036 Shares of Stock

June 25, 2025 | marketbeat.com

5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings Call

June 25, 2025 | msn.com

Oppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 25, 2025 | marketbeat.com

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

June 24, 2025 | bakersfield.comB

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

June 24, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, UTHR, SRPT, and TEVA Company Descriptions

Legend Biotech NASDAQ:LEGN

$34.63 +1.15 (+3.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$35.20 +0.57 (+1.64%)

As of 06/27/2025 07:39 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sarepta Therapeutics NASDAQ:SRPT

$17.11 -0.12 (-0.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$17.30 +0.19 (+1.11%)

As of 06/27/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Teva Pharmaceutical Industries NYSE:TEVA

$16.76 +0.20 (+1.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$16.65 -0.10 (-0.60%)

As of 06/27/2025 08:00 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

United Therapeutics NASDAQ:UTHR

$284.27 +0.18 (+0.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$282.42 -1.84 (-0.65%)

As of 06/27/2025 05:34 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time